Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Hemostemix Inc

HEM.V ✓ COMPLIANTFree checks used up today ☆ Track — members

TSX · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: N/A

Last Close

$0.04

▼ -16.67%

Market Cap $7.83M · Vol 56.71K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$7.83M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

33.33

Momentum

Beta

0.71

vs Market

52W High

$0.08

54.94% below

52W Low

$0.03

23.70% above

Volume

56.71K

Avg 36.31K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

83.95%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Hemostemix Inc (HEM.V) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HEM.V pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-9.09%

-16.67%

YTD

-44.44%

-50.00%

-34.89%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-3,434,808.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-512.73% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	219.05M

Technical Indicators

50-Day SMA	$0.05
200-Day SMA	$0.05
RSI (14)	33.33
Beta	0.71
52-Week High	$0.08
52-Week Low	$0.03

Volume Today	56.71K
Avg Daily Volume (30D)	36.31K
Relative Volume	1.56x
Volatility (10D)	117.31
Volatility (30D)	121.59
Free Float	83.95%

Analyst Consensus

N/A

Current Price $0.04

Mean Target N/A

52W Low$0.03 52W High$0.08

Current

Target

$0.03 $0.08

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX

FIGIBBG0038N5RX3

ISINCA4236943060

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.22% ARGX.BR argenx SE -2.87% ARGX argenx SE -2.00% GMAB.CO Genmab A/S -5.47% GMAB Genmab A/S -3.75%

Company Profile

Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.